Bayer/GlaxoSmithKline Levitra EU opinion
This article was originally published in Pharmaceutical Approvals Monthly
Bayer/GSK's erectile dysfunction therapy Levitra (vardenafil) receives a positive opinion Nov. 21 from European Committee for Proprietary Medicinal Products. Bayer says the opinion was received earlier than anticipated. Levitra 10 mg and 20 mg were shown to have 82% and 86% average success rates, respectively, in data presented at the European Society for Sexual and Impotence Research in early December. The companies anticipate a first-half 2003 European launch; U.S. approval is also expected in 200
You may also be interested in...
Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.
Acquiring Clarion Brands from Swander Pace, Bridges Consumer Healthcare adds portfolio of OTC and supplement brands for symptoms including tinnitus, urinary pain relief and excessive sweating.
The document from the Medical Device Innovation Consortium aggregates external data sources, various statistical methods and lays out other considerations for sponsors to help speed up and bolster a premarket product application to the US FDA.